December 13, 2023
Jennifer Wonnacott, Chief External Affairs Officer
SACRAMENTO — This morning, the U.S. Supreme Court agreed to take up the Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration case. The Court granted only the FDA’s and Danco’s petitions, which asked the Court to review the Fifth Circuit’s decision to turn back the clock on mifepristone approval to 2015. The Court denied the cross-petition filed by AHM, which asked the Court to reverse the FDA’s 2000 approval of mifepristone. This means that access and approval to mifepristone remains unchanged.
Statement from Jodi Hicks, President/CEO of Planned Parenthood Affiliates of California:
“First and foremost, the Supreme Court announcement today does not change access to or approval of mifepristone, including in California for now, but let's be clear; we should not be having this fight in the first place to keep safe and effective abortion medication accessible for all who need it.
“The Supreme Court should reverse the extreme decision of the lower courts that comes from a political motivated attempt to strip access to medication abortion and keep mifepristone available without unnecessary restrictions – anything less would effectively be taking the country one step closer to a national abortion ban. We should not be having to fight ideological judges who ignore medical and scientific evidence to dictate the care providers can offer patients. The courts should not be deciding what someone can do with their own body. Everyone deserves access to abortion care without interference.
“Despite extremists claims and attacks, and the chaos and confusion they have created, mife is safe, effective, and continues to be accessible. Planned Parenthood will keep fighting to make sure it stays that way, and everyone can make their own decisions about their bodies, lives, and futures.”
The schedule for oral arguments or decision is unknown at this time, but arguments will likely take place in the Spring with a decision by the end of June.